A polymer/oil based nanovaccine as a single-dose immunization approach

Area of Science:

• Nanotechnology
• Immunology
• Vaccine Development

Background:

• Developing novel antigen delivery carriers is crucial for improving vaccine efficacy.
• Existing carriers often require additional immunostimulants to achieve desired immune responses.
• There is a need for carriers that can modulate and prolong immune responses effectively.

Purpose of the Study:

• To characterize a novel chitosan nanocapsule (CSNC) system for antigen delivery.
• To evaluate the impact of antigen organization on the nanocarrier surface on immune response.
• To assess the long-term immunopotentiating effect of CSNC without additional adjuvants.

Main Methods:

• Development of two CSNC prototypes (CSNC+ and CSNC-) with varying surface antigen organization and charge.
• Characterization of particle size, antigen association efficiency, and surface properties.
• In vivo evaluation of nanovaccine immunogenicity following intramuscular vaccination in a model antigen system (rHBsAg).

Main Results:

• CSNC+ demonstrated superior neutralizing antibody responses compared to CSNC- and alum-rHBsAg.
• A single dose of CSNC+ achieved IgG levels comparable to the positive control.
• CSNC+ elicited a mixed Th1/Th2 immune response, unlike the Th2-biased response induced by alum.
• CSNC+ exhibited stability after freeze-drying, retaining its physicochemical properties and in vivo adjuvant effect.

Conclusions:

• CSNC+ is a promising multifunctional nanocarrier for enhancing, prolonging, and modulating immune responses to subunit antigens.
• The surface antigen organization significantly influences the nanocarrier's immunopotentiating capacity.
• CSNC+ offers a stable and effective alternative to traditional vaccine adjuvants.